Evidence map›Paper›PMID 27372070›Full record

ReviewBreast cancer research and treatment2016

Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.

Jamunarani Veeraraghavan, Jiacheng Ma, Yiheng Hu, Xiao-Song Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Computational methods for detecting cancer hotspots.Computational and structural biotechnology journal · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jamunarani VeeraraghavanLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA.
Jiacheng MaLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA.
Yiheng HuLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA.
Xiao-Song WangLester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA. wangx13@pitt.edu.

Funding

CHARACTERIZATION OF RECURRENT ADJACENT GENE TRANSLOCATIONS IN BREAST CANCERR01CA183976 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, XIAOSONG · 2014 to 2019
$1.6M
Integrative Consig: NLK as Attractive Drug Target for Intractable Breast CancerR01CA181368 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, XIAOSONG · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA181368NCI NIH HHS R01 CA183976
6 · The paper itself

Abstract

Gene fusions have long been considered principally as the oncogenic events of hematologic malignancies, but have recently gained wide attention in solid tumors due to several milestone discoveries and the advancement of deep sequencing technologies. With the progress in deep sequencing studies of breast cancer transcriptomes and genomes, the discovery of recurrent and pathological gene fusions in breast cancer is on the focus. Recently, driven by new deep sequencing studies, several recurrent or pathological gene fusions have been identified in breast cancer, including ESR1-CCDC170, SEC16A-NOTCH1, SEC22B-NOTCH2, and ESR1-YAP1 etc. More important, most of these gene fusions are preferentially identified in the more aggressive breast cancers, such as luminal B, basal-like, or endocrine-resistant breast cancer, suggesting recurrent gene fusions as additional key driver events in these tumors other than the known drivers such as the estrogen receptor. In this paper, we have comprehensively summarized the newly identified recurrent or pathological gene fusion events in breast cancer, reviewed the contributions of new genomic and deep sequencing technologies to new fusion discovery and the integrative bioinformatics tools to analyze these data, highlighted the biological relevance and clinical implications of these fusion discoveries, and discussed future directions of gene fusion research in breast cancer.

Indexed as

Gene FusionBreast NeoplasmsFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenomicsHigh-Throughput Nucleotide SequencingHumansSequence Analysis, DNABioinformaticsBreast cancerGenomicsNext-generation sequencingRecurrent gene fusionsTumorigenesis

Identifiers

PMID27372070
PMCPMC4979600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.